Literature DB >> 33946285

Distinguishing Alzheimer's Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis.

Jay S Hanas1,2,3, James R S Hocker1, Christian A Vannarath1, Megan R Lerner2, Scott G Blair2, Stan A Lightfoot3, Rushie J Hanas1, James R Couch4, Linda A Hershey4.   

Abstract

It is important to develop minimally invasive biomarker platforms to help in the identification and monitoring of patients with Alzheimer's disease (AD). Assisting in the understanding of biochemical mechanisms as well as identifying potential novel biomarkers and therapeutic targets would be an added benefit of such platforms. This study utilizes a simplified and novel serum profiling platform, using mass spectrometry (MS), to help distinguish AD patient groups (mild and moderate) and controls, as well as to aid in understanding of biochemical phenotypes and possible disease development. A comparison of discriminating sera mass peaks between AD patients and control individuals was performed using leave one [serum sample] out cross validation (LOOCV) combined with a novel peak classification valuation (PCV) procedure. LOOCV/PCV was able to distinguish significant sera mass peak differences between a group of mild AD patients and control individuals with a p value of 10-13. This value became non-significant (p = 0.09) when the same sera samples were randomly allocated between the two groups and reanalyzed by LOOCV/PCV. This is indicative of physiological group differences in the original true-pathology binary group comparison. Similarities and differences between AD patients and traumatic brain injury (TBI) patients were also discernable using this novel LOOCV/PCV platform. MS/MS peptide analysis was performed on serum mass peaks comparing mild AD patients with control individuals. Bioinformatics analysis suggested that cell pathways/biochemical phenotypes affected in AD include those involving neuronal cell death, vasculature, neurogenesis, and AD/dementia/amyloidosis. Inflammation, autoimmunity, autophagy, and blood-brain barrier pathways also appear to be relevant to AD. An impaired VWF/ADAMTS13 vasculature axis with connections to F8 (factor VIII) and LRP1 and NOTCH1 was indicated and is proposed to be important in AD development.

Entities:  

Keywords:  Alzheimer’s disease (AD); SSPO AD biomarker; VWF/ADAMTS13 axis; biochemical phenotype analysis; mass spectrometry; serum profiling; traumatic brain injury (TBI)

Year:  2021        PMID: 33946285     DOI: 10.3390/brainsci11050583

Source DB:  PubMed          Journal:  Brain Sci        ISSN: 2076-3425


  77 in total

Review 1.  mRNA metabolism and neuronal disease.

Authors:  Bastian Linder; Utz Fischer; Niels H Gehring
Journal:  FEBS Lett       Date:  2015-05-13       Impact factor: 4.124

2.  ADAMTS13 and von Willebrand factor interactions.

Authors:  Catherine B Zander; Wenjing Cao; X Long Zheng
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

3.  Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients.

Authors:  James R Hocker; Subrato J Deb; Min Li; Megan R Lerner; Stan A Lightfoot; Aurelien A Quillet; R Jane Hanas; Matthew Reinersman; Jess L Thompson; Nicole T Vu; Thomas C Kupiec; Daniel J Brackett; Marvin D Peyton; Stephen M Dubinett; Harold M Burkhart; Russell G Postier; Jay S Hanas
Journal:  Cancer Invest       Date:  2017-09-26       Impact factor: 2.176

4.  NOTCH1 signaling induces pathological vascular permeability in diabetic retinopathy.

Authors:  Khalil Miloudi; Malika Oubaha; Catherine Ménard; Agnieszka Dejda; Vera Guber; Gael Cagnone; Ariel M Wilson; Nicolas Tétreault; Gaëlle Mawambo; Francois Binet; Rony Chidiac; Chantal Delisle; Manuel Buscarlet; Agustin Cerani; Sergio Crespo-Garcia; Katie Bentley; Flavio Rezende; Jean-Sebastien Joyal; Frédérick A Mallette; Jean-Philippe Gratton; Bruno Larrivée; Przemyslaw Sapieha
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-20       Impact factor: 11.205

5.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.

Authors:  Sebastian Palmqvist; Shorena Janelidze; Yakeel T Quiroz; Henrik Zetterberg; Francisco Lopera; Erik Stomrud; Yi Su; Yinghua Chen; Geidy E Serrano; Antoine Leuzy; Niklas Mattsson-Carlgren; Olof Strandberg; Ruben Smith; Andres Villegas; Diego Sepulveda-Falla; Xiyun Chai; Nicholas K Proctor; Thomas G Beach; Kaj Blennow; Jeffrey L Dage; Eric M Reiman; Oskar Hansson
Journal:  JAMA       Date:  2020-08-25       Impact factor: 56.272

Review 6.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

7.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.

Authors:  Suzanne E Schindler; James G Bollinger; Vitaliy Ovod; Kwasi G Mawuenyega; Yan Li; Brian A Gordon; David M Holtzman; John C Morris; Tammie L S Benzinger; Chengjie Xiong; Anne M Fagan; Randall J Bateman
Journal:  Neurology       Date:  2019-08-01       Impact factor: 11.800

Review 8.  Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link.

Authors:  Jaime Ramos-Cejudo; Thomas Wisniewski; Charles Marmar; Henrik Zetterberg; Kaj Blennow; Mony J de Leon; Silvia Fossati
Journal:  EBioMedicine       Date:  2018-01-31       Impact factor: 8.143

9.  Von Willebrand factor and ADAMTS13 activity in relation to risk of dementia: a population-based study.

Authors:  Frank J Wolters; Johan Boender; Paul S de Vries; Michelle A Sonneveld; Peter J Koudstaal; Moniek P de Maat; Oscar H Franco; M Kamran Ikram; Frank W Leebeek; M Arfan Ikram
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

10.  Microcephaly with altered cortical layering in GIT1 deficiency revealed by quantitative neuroimaging.

Authors:  Alexandra Badea; Robert Schmalzigaug; Woojoo Kim; Pamela Bonner; Umer Ahmed; G Allan Johnson; Gary Cofer; Mark Foster; Robert J Anderson; Cristian Badea; Richard T Premont
Journal:  Magn Reson Imaging       Date:  2020-09-30       Impact factor: 2.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.